Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial
Condition.
On May8, 2017, Eagle Pharmaceuticals,Inc., or the Company, issued
a press release announcing its financial results for the quarter
ended March31, 2017. A copy of the Companys press release is
furnished as Exhibit99.1 to this Current Report on Form8-K and is
incorporated herein by reference.
The information in this Current Report on Form8-K, including the
information contained in the press release furnished as
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, or otherwise subject to the liabilities of that
section, and shall not be deemed incorporated by reference into
any of the Companys filings under the Securities Act of 1933, as
amended or the Exchange Act, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release of the Company dated May8, 2017 |
About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas. Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information
Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session up +0.27 at 31.14 with 5,403,345 shares trading hands.